[1]Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC [2]Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters [3]Ⅳ期寡转移NSCLC同期放化疗后巩固化疗前瞻性Ⅱ期临床研究 [4]Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China [5]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [6]A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer [7]KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review [8]Antibiotic use is a negative predictor of the efficacy and toxicity of epidermal growth factor receptor-targeted therapy in advanced non-small cell lung cancer. [9]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [10]The Role of Thoracic Vertebral Body Dosimetry in Minimizing Acute Hematologic Toxicities of Non-Small Cell Lung Cancer Patients Receiving Lung Radiotherapy and Immunotherapy